Mei Chen

Dr. Mei Chen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2014 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
HZHongyan Zhang
Hongyan Zhang
XWXuwei Wu
Xuwei Wu
YXYi Xiao
Yi Xiao
MCMei Chen
Mei Chen
ZLZhidong Li
Zhidong Li
KTKaifa Tang
Kaifa Tang
Our objective is to investigate the genetic polymorphisms of the glutathione S-transferase M1 and T1 genes (GSTM1 and GSTT1) and evaluate oxidative damage in patients with non-small lung cancer (N-SCLC). One hundred and ten patients with N-SCLC and 100 controls are included in this case-control study. Multiplex polymerase chain reaction (PCR) analyses were used to identify the genotypes. The activities of malondialdehyde (MDA) and nitric oxide (NO) and total antioxidant capacity (T-AOC) were detected by spectroscopic analysis. The frequencies of the GSTM1, T1, and GSTM1/T1 null genotypes in the patient group were significantly higher than that in the control group (OR = 2.071, P = 0.009; OR = 1.900, P = 0.024; OR = 3.258, P = 0.003). The activities of MDA and NO were significantly higher in the patient group than that in the control group (P <0.001), and T-AOC was significantly lower in patient group than that in control group (P <0.001). The activities of MDA, and NO were higher but the T-AOC was lower in patients with the GSTM1, T1 and M1/T1 null genotypes than those in patients with GSTM1, T1 and M1/T1 present genotypes (P <0.001). Our results suggest that oxidative damage may be play a important role in patients with N-SCLC, and that GSTM1 and GSTT1 null genotypes may predispose the cells of patients with N-SCLC to increased oxidative damage.

23 June 2026 in The Egyptian Journal of Bronchology
Verified
Journal Article
Open access
PDF file
FQFu Qian
Fu Qian
LQLiu Qiang
Liu Qiang
LCLiu Chanli
Liu Chanli
SCSun Caiyuan
Sun Caiyuan
XCXiong Chan
Xiong Chan
MCMei Chen
Mei Chen
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterized by progressive airflow limitation. The management paradigm is shifting from reactive symptom control toward proactive strategies centered on “disease activity”. Mucus plugs Score (MPS), derived from computed tomography (CT), provides a visual assessment of occlusive airway plugs. As a promising alternative imaging biomarker, MPS correlates with disease activity and may guide precision interventions to achieve “low disease activity state (LDAS)”. Objective: This study explores the comprehensive utility of MPS as a novel imaging biomarker in COPD, specifically for assessing disease activity, optimizing risk stratification for exacerbations and mortality, and guiding individualized therapeutic strategies. Methods: A comprehensive literature search was conducted in PubMed and Web of Science for articles published from database inception through March 2026. The search strategy employed a combination of MeSH terms and keywords, including “Chronic Obstructive Pulmonary Diseases”, “Chronic Obstructive Lung Disease”, “Pulmonary Disease, Chronic Obstructive”, “Chronic Obstructive Airway Disease”, “COAD”, “COPD”, “Airflow Obstruction, Chronic”, “Chronic Airflow Obstructions”, “mucus plugs”, “mucus plugging”, “mucus plugs score”, “MPS” and “disease activity”. Articles were included based on their relevance to CT-detected mucus plugs, pathophysiology, and associated clinical outcomes in COPD. Priority was given to randomized controlled trials, prospective or retrospective observational cohorts, and high-quality mechanistic studies. Non-peer-reviewed materials and duplicate reports were excluded. Results: Mucus plugs formation is a complex pathophysiological process involving mucus hypersecretion, impaired mucociliary clearance, and inflammatory cross-linking. Together, these mechanisms produce highly viscous, occlusive obstructions. Recent longitudinal cohort studies confirm that a high MPS is an independent risk factor for adverse clinical outcomes in COPD, including increased frequency of moderate-to-severe exacerbations, accelerated annual decline in FEV₁, and elevated all-cause mortality. Based on this evidence, MPS is thus recognized as a biomarker associated with disease progression and a potential factor in its worsening. Notably, “silent” mucus plugs in asymptomatic patients predict rapid progression and poor prognosis, presenting risks comparable, or even worse than symptomatic phenotypes. Conclusion: MPS is a promising imaging biomarker that quantifies the burden of airway obstruction and reflects the disease activity of COPD. It may offer a more objective and direct assessment of COPD disease activity, serving as a valuable complement to traditional clinical indicators. Furthermore, our analysis demonstrates that MPS can identify high-risk “silent” asymptomatic patients who are otherwise overlooked by standard symptom-based assessments. MPS can independently predicts the risk of acute exacerbations, accelerated decline in FEV₁, and all-cause mortality, facilitating superior risk stratification. By identifying mucus plugs as a “treatable trait”, this biomarker enables a more precise targeted application of mucoactive and biologic therapies. We propose that MPS could serves as a complementary clinical tool for achieving the management goal of LDAS and improving long-term prognostic outcomes in patients with COPD.

2 July 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
YLYue Liu
Yue Liu
QHQingsong Huang
Qingsong Huang
ZZZhenhua Zhuang
Zhenhua Zhuang
HYHongjing Yang
Hongjing Yang
XGXiaoling Gou
Xiaoling Gou
GFGang Fan
Gang Fan
Chronic obstructive pulmonary disease (COPD) is one of the primary causes of mortality and morbidity worldwide. The gut microbiome, particularly the bacteriome, has been demonstrated to contribute to the progression of COPD. However, the influence of gut virome on the pathogenesis of COPD is rarely studied. Recent advances in viral metagenomics have enabled the rapid discovery of its remarkable role in COPD. In this study, deep metagenomics sequencing of fecal virus-like particles and bacterial 16S rRNA sequencing was performed on 92 subjects from China to characterize alterations of the gut virome in COPD. Lower richness and diversity of the gut virome were observed in the COPD subjects compared with the healthy individuals. Sixty-four viral species, including Clostridium phage , Myoviridae sp., and Synechococcus phage , showed positive relationships with pulmonary ventilation functions and had markedly declined population in COPD subjects. Multiple viral functions, mainly involved in bacterial susceptibility and the interaction between bacteriophages and bacterial hosts, were significantly declined in COPD. In addition, COPD was characterized by weakened viral-bacterial interactions compared with those in the healthy cohort. The gut virome showed diagnostic performance with an area under the curve (AUC) of 88.7%, which indicates the potential diagnostic value of the gut virome for COPD. These results suggest that gut virome may play an important role in the development of COPD. The information can provide a reference for the future investigation of diagnosis, treatment, and in-depth mechanism research of COPD. IMPORTANCE: Previous studies showed that the bacteriome plays an important role in the progression of chronic obstructive pulmonary disease (COPD). However, little is known about the involvement of the gut virome in COPD. Our study explored the disease-specific virome signatures of patients with COPD. We found the diversity and compositions altered of the gut virome in COPD subjects compared with healthy individuals, especially those viral species positively correlated with pulmonary ventilation functions. Additionally, the declined bacterial susceptibility, the interaction between bacteriophages and bacterial hosts, and the weakened viral-bacterial interactions in COPD were observed. The findings also suggested the potential diagnostic value of the gut virome for COPD. The results highlight the significance of gut virome in COPD. The novel strategies for gut virome rectifications may help to restore the balance of gut microecology and represent promising therapeutics for COPD.

7 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMei Yang
Mei Yang
YTYuying Tan
Yuying Tan
TYTing Yang
Ting Yang
DXDan Xu
Dan Xu
MCMei Chen
Mei Chen
LCLei Chen
Lei Chen
Background: The therapeutic role of antifibrotic therapy has been well-established in idiopathic pulmonary fibrosis (IPF). However, its efficacy and safety for interstitial lung diseases (ILDs) other than IPF are not fully understood. Methods: We updated a systematic review with meta-analysis and trial sequential analysis (TSA) of randomized controlled trials and prospective studies on antifibrotic drug (nintedanib or pirfenidone) vs other intervention (placebo, no intervention or conventional treatment) in non-IPF ILDs. The primary outcomes were absolute change in forced vital capacity (FVC), all-cause mortality and serious adverse events (SAEs). The risk of bias was rated with the RoB2 tool and certainty of evidence was assessed by the GRADE approach. Results: 17 studies with 1908 patients were included. For the primary outcomes, pooled analyses of four trials with low risk of bias showed that antifibrotic drugs significantly ameliorated FVC decline (mean difference 86.21; 95% CI 49.38 to 123.03; I2 = 64%; TSA-adjusted CI 40.86 to 131.56). Based on five trials with low risk of bias, no difference was observed in all-cause mortality (RR 0.87; 95% CI 0.53 to 1.43; I2 = 0%; TSA-adjusted CI 0.12 to 6.53) and SAEs (RR 0.97; 95% CI 0.83 to 1.13; I2 = 0%; TSA-adjusted CI 0.74 to 1.28) between groups. However, based on two studies with 324 patients, benefit of antifibrotic drugs in FVC was not shown in the subgroup taking mycophenolate (mean difference 17.08; 95% CI -56.22 to 90.37), which also had higher risk of SAEs (RR 1.71; 95% CI 1.09 to 2.70), although both were contested by TSA. Conclusion: Our study suggests that antifibrotic drugs are beneficial for patients with non-IPF ILDs in slowing disease progression, whereas may not correlate to all-cause mortality and SAEs. However, for patients taking mycophenolate, antifibrotic drugs may do more harm than good. More investigations are warranted to validate current findings.

27 November 2023 in Thoracic Cancer
Verified
Journal Article
Open access
SWShuyan Wang
Shuyan Wang
JAJing An
Jing An
XHXueru Hu
Xueru Hu
TZTingting Zeng
Tingting Zeng
PLPing Li
Ping Li
FWFuqiang Wen
Fuqiang Wen
We used 10 × genomics single‐cell transcriptome sequencing technology to reveal the tumor immune microenvironment characteristics of small cell lung cancer (SCLC) in a patient with malignant pleural effusion (MPE). A total of 8008 high‐quality cells were finally obtained for subsequent bioinformatic analysis, which were divided into 10 cell clusters further identified as B cells, T cells, myeloid cells, NK cells, and cancer cells. Such SCLC related genes as NOTCH1, MYC, TSC22D1, SOX4, BLNK, YBX3, VIM, CD8A, CD8B, and KLF6 were expressed in different degrees during differentiation of T and B cells. Different ligands and receptors between T, B and tumor cells almost interact through MHC II, IL‐16, galectin, and APP signaling pathway.

7 November 2022 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
YLYue Liao
Yue Liao
YWYanqiu Wu
Yanqiu Wu
KZKai Zi
Kai Zi
YSYongchun Shen
Yongchun Shen
TWTao Wang
Tao Wang
JCJun Chen
Jun Chen
Background: N-acetylcysteine (NAC), which is specifically involved in airway mucus clearance and antioxidation, is recommended by the treatment guideline for non-cystic fibrosis bronchiectasis (NCFB). However, there is little clinical evidence of its long-term efficacy concerning quality of life (QoL) and exacerbation in patients with NCFB. In addition, the influences of NAC on airway bacterial colonization, chronic inflammation and oxidative stress in NCFB are also unclear. Methods: NINCFB is a prospective, multicentre, double-blind, randomised, placebo-controlled trial that will recruit 119 patients with NCFB and randomly divide them into an NAC group (n = 79) and a control group (n = 40). Participants in the NAC group will receive 600 mg oral NAC twice daily for 52 weeks, while patients in the control group will receive 600 mg placebo twice daily for 52 weeks. The information at baseline will be collected once participants are enrolled. The primary endpoints are the changes in St George’s Respiratory Questionnaire scores and the number of exacerbations in 52 weeks. The secondary endpoints are the 16S rRNA of sputum and the levels of inflammatory factors and oxidative stressors in sputum and serum. Other data related to radiography, lung function tests, number of oral and/or intravenous antibiotic therapies and adverse events (AEs) will also be analysed. Further subgroup analysis distinguished by the severity of disease, severity of lung function, airway bacterial colonization and exacerbation frequency will be performed. Discussion: The objective of this study is to determine the long-term efficacy of NAC on QoL and exacerbation of NCFB and to explore the effectiveness of NAC for antibiosis, anti-inflammation and antioxidation in NCFB. The study results will provide high-quality clinical proof for the revision and optimization of treatment guidelines and for expert consensus on NCFB treatment. Trial registration: The trial was registered on the Chinese Clinical Trial Register at April 11, 2020 (chictr.org.cn, ChiCTR2000031817).